Navigation Links
Nuvelo Announces Presentation on NU206 at 2007 American Association,for Cancer Research Annual Meeting

on Kirin Brewery's Pharmaceutical Division, please visit its website at http://www.kirin.co.jp/english/index.html.

This press release contains "forward-looking statements," which include statements regarding the potential uses of NU206 to treat various conditions, the timing and progress of Nuvelo's clinical stage and preclinical research programs, and the potential utility of other Nuvelo compounds to treat particular indications, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patients in our clinical trials; and dependence upon strategic partners for the performance of critical activities under collaborative agreements. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Annual Report on Form 10-K for the year ended December 31, 2006 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

CONTACT: Shelly Guyer of VP of Business Development & IR, +1-650-517-8437, or , for Nuvelo; or Danielle Bertrand of WeissCommPartners, Inc., +1-415-946-1056, or , forNuvelo sguyer@nuvelo.com dbertrand@weisscommpartners.com

Web site: http://www.nuvelo.com/

Ticker Symbol: (NASDAQ-NMS:NU
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:10/7/2008)... In a clinical study of adults, VYVANSE taken ...ADHD within one week, PHILADELPHIA, Oct. 7 /PRNew...HPGY), the global specialty biopharmaceutical comp... September issue of the Journal of,Clinical Psychi...ed,Attention Deficit Hyperactivity Disorder (ADHD)...
(Date:10/7/2008)... - Data Presented Today at ACG Annual Sci...ire-FirstCall/ -- Ironwood,Pharmaceuticals, Inc. (...Inc. (NYSE: FRX ) today announced the presentatio...lotide,s safety and efficacy in 420 patients with,.... Analysis of the data,indicates that once- daily ...
(Date:10/7/2008)... BERKELEY, Calif., Oct. 7 /- Aero... safety data from a Phase I trial of its Aerovant,...ty with no evidence of,local irritancy following a..., This 10 mg dose will be the highest of three do...ging study, which is scheduled to begin early,next...
(Date:10/7/2008)... 125 Patient, Prospective Randomized Placebo-Contr...Significant Improved Overall Survival., MOUNTAIN ...unoTherapeutics has now evaluated the mature Phase...ine candidate PROSTVAC(TM) that had been,obtained ...he National,Cancer Institute (NCI) in the US., Th...
Breaking Medicine Technology:Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5Data Show Aerovance's Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 1Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3847 10Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 1Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 2Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 3Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 4Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 5Peregrine Pharmaceuticals Announces Positive Data From Cotara 28R 29 Brain Cancer Trials 13980 6ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 1ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo Including the Worlds Largest Catalog of Validated Ion C 3841 2Gender bias may affect care of people with osteoarthritis study finds 13976 1Gender bias may affect care of people with osteoarthritis study finds 13976 2
...7 - Novelos,Therapeutics, Inc. (OTCBB: NVLT), a bi... of therapeutics to treat cancer and,hepatitis, to...na-Farber/Partners Cancer Care (DF/PCC) Phase 2 tr...platinum-resistant ovarian,cancer patients. To dat...or response (assessed at least after 8 weeks / 2,c...
...m versus placebo: - 25,/ - 13 mm Hg (systolic / di...n vaccine dose and induced,antiangiotensin II anti... the Seventeenth European,Meeting on Hypertension ... and MILAN, Italy, June 17, 2007 -,Cytos Biotechno...ta,on its hypertension vaccine CYT006-AngQb at the...
Other Medicine Technology:Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 2Novelos Therapeutics Announces Encouraging Results in Ongoing Phase,2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 2Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 3Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 4Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 5Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 6Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 7Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 8Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur 9
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ntists from the University of Cincinnati have come...ood obesity.// This issue has become an important...ety. In the spring season the researchers recruite...m in Meade County, Ky to fight childhood obesity. ...
...rding to the scientist from the Victorian Breast C...east stem cells which have undergone some mutation...ancers.// The Walter and Eliza Hall Institute res...en they found that the breast stem cells do not ex...
...w research conducted by consumer organization Whic...s contain high levels of fat, salt and sugar. Of...hecked for sugar, salt and fat content using the F...three-quarters had a high level of sugars, while a...
...recent announcements by Health Minister, Tony Abbo...ic health enemy No.1, has failed to impress AMA Pr...e initiatives to be much more forceful so that pro... The minister had announced a new ministerial t...
Other Medicine News:Health News:New Preventive Strategy to Fight Childhood Obesity 2Health News:Mutation in Breast Stem Cells Lead to Breast Cancer 2
...eica ASP200 is an advanced smart processor for par...ne histopathology applications. Proven and enhance... smart operating software are the hallmark of the ...ed and the software includes a variety of SMART fe...
The electronic, motorized rotary microtomes are designed for all applications of paraffin, semi-thin (HM 360), and hard specimens in clinical, research, and industrial labs. These instruments display
...eica RM2255 rotary microtome, designed for fully m...bedded specimens, offers a broad application spect...ory. This microtome meets the requirements of user...c microtome for their laboratory. The entire acces...
State-of-the-Art modular embedding station providing performance and ease of use to meet the needs of the most demanding user.
Medicine Products: